Sight Sciences, Inc. Common Stock (SGHT) is a publicly traded Healthcare sector company. As of November 5, 2026, SGHT trades at $9.68 with a market cap of $533.25M and a P/E ratio of -14.76. SGHT moved +1.08% today. Year to date, SGHT is +26.65%; over the trailing twelve months it is +94.14%. Its 52-week range spans $2.03 to $10.28. Analyst consensus is strong buy with an average price target of $10.17. Rallies surfaces SGHT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sight Sciences raises 2026 revenue outlook as Q3 revenue grows 25% and OMNI Ultra launches: Sight Sciences raised its 2026 revenue guidance to $92 million-$93 million after third-quarter revenue rose 25% year over year to $24.9 million and net loss narrowed 17% to $6.8 million. Year-to-date revenue rose 19% to $68 million, and the company launched its OMNI Ultra Surgical System.
| Metric | Value |
|---|---|
| Price | $9.68 |
| Market Cap | $533.25M |
| P/E Ratio | -14.76 |
| EPS | $-0.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.28 |
| 52-Week Low | $2.03 |
| Volume | 1.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $83.38M |
| Net Income | $-29.76M |
| Gross Margin | 87.96% |
8 analysts cover SGHT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.17.